RecruitingPhase 3NCT07062978

A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

A Multicenter, Randomized, Double-blind Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

Sponsor

Qilu Pharmaceutical Co., Ltd.

Enrollment

278 participants

Start Date

Jun 27, 2025

Study Type

INTERVENTIONAL

Conditions

Postmenopausal Women With Osteoporosis at High Risk of Fracture

Summary

This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.

Eligibility

Sex: FEMALEMin Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Prolia® and a drug called QL1206 for people with postmenopausal women with osteoporosis at high risk of fracture. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 50 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGQL1206

QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

DRUGProlia®

Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.

Locations(1)

Zhejiang Provincial People's Hospital Bijie Hospital

Guizhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07062978